$1.15
-0.03 (-2.54%)
Open$1.18
Previous Close$1.18
Day High$1.23
Day Low$1.12
52W High$8.81
52W Low$0.92
Volume—
Avg Volume74.5K
Market Cap6.09M
P/E Ratio—
EPS$-7.19
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+900.0% upside
Current
$1.15
$1.15
Target
$11.50
$11.50
$7.99
$11.50 avg
$12.09
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.17M | 987.4K | 951.3K |
| Net Income | -629,164,144 | -74,062 | -66,038 |
| Profit Margin | -374.3% | -7.5% | -6.9% |
| EBITDA | -513,498,365 | -123,235 | -109,691 |
| Free Cash Flow | — | -44,936 | -40,091 |
| Rev Growth | — | +23.6% | +13.9% |
| Debt/Equity | — | 1.06 | 0.89 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |